HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME
Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
1 - 31 . (canceled)
32 . A polypeptide construct comprising an ankyrin-like repeat domain and an HPV peptide.
33 . The polypeptide construct of claim 32 , wherein the ankyrin-like repeat protein is a human ankyrin-like repeat protein.
34 . (canceled)
35 . The polypeptide construct of claim 32 , wherein the HPV peptide is an HPV-16 peptide or an HPV-18 peptide.
36 . The polypeptide construct of claim 32 , wherein the HPV peptide is:
an HPV-16 E5 peptide;
an HPV-16 E6 peptide;
an HPV-16 E7 peptide;
an HPV-18 E6 peptide; or
an HPV-18 E7 peptide.
37 . The polypeptide construct of claim 32 , wherein the HPV peptide is:
an HPV-16 E5 peptide of SEQ ID NO: 130;
an HPV-16 E6 peptide of any one of SEQ ID NOs: 113-121;
an HPV-16 E7 peptide of any one of SEQ ID NOs: 122-129;
an HPV-18 E6 peptide of any one of SEQ ID NOs: 131-138; or
an HPV-18 E7 peptide of any one of SEQ ID NOs: 139-144.
38 . The polypeptide construct of claim 32 , comprising the amino acid sequence of SEQ ID NO: 52.
39 . The polypeptide construct of claim 32 , further comprising at least one agonist peptide.
40 . The polypeptide construct of claim 39 , comprising the amino acid sequence of SEQ ID NO: 54.
41 - 45 . (canceled)
46 . A polynucleotide encoding the polypeptide construct of claim 32 .
47 . A vector comprising the polynucleotide of claim 46 .
48 . The vector of claim 47 , wherein the vector is an adenoviral vector.
49 . The vector of claim 48 , wherein the adenoviral vector is a gorilla adenoviral vector.
50 . (canceled)
51 . The polypeptide construct of claim 32 , wherein the ankyrin-like repeat protein is a human ankyrin-like repeat protein.
52 . The polypeptide construct of claim 32 , comprising the amino acid sequences of each of SEQ ID NOs: 113-144.
53 . The vector of claim 49 , wherein the gorilla adenoviral vector does not comprise an E1 region.
54 . The vector of claim 49 , wherein the gorilla adenoviral vector does not comprise an E4 region.
55 . The vector of claim 49 , wherein the gorilla adenoviral vector does not comprise an E1 region or an E4 region.
56 . The vector of claim 49 , wherein the gorilla adenoviral vector is a GC46 vector.
57 . The vector of claim 49 , wherein the polynucleotide is under the control of an immediate early cytomegalovirus (CMV) promoter.
58 . A method of vaccinating a subject against human papilloma virus, the method comprising administering to the subject the vector of claim 49 .